Topiramate vs sodium valproate in treating refractory epilepsy
- VernacularTitle:托吡酯与丙戊酸钠缓释片治疗难治性癫痫疗效比较
- Author:
Huijun XIE
;
Cuiling ZHOU
;
Suju DING
;
Huimin ZHENG
- Publication Type:Journal Article
- From:
Chinese Journal of New Drugs and Clinical Remedies
2001;20(2):90-93
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To compare the effects between topiramate and slow-release sodium valproate in treating refractory epilepsy. METHODS: Topiramate group of 39 patients (M 21, F 18; age 28 a± s 20 a) was compared with sodium valproate group of 41 patients (M 22, F 19; age 27 a±17 a) in antiepileptic effect of refractory epilepsy. Adult's and children's dosages of topiramate were increased gradually about 200 mg*d-1 and 4 mg*kg*d-1 respectively during about 2 mo, po, bid, for 6 mo as a course. Adult's dosage of slow-release sodium valproate was 0.5-1 g*d-1, and children's was increased gradually to total dosage: 15-30 mg*kg*d-1, po, qd or bid (morning or morning and noon), for 6 mo as a course. Effects were analysed between these two drugs after treatment 4 and 6 mo. RESULTS： Simple and complex partial seizures with or without secondary generalized seizure, in topiramate group were much more improved than these in sodium valproate group 6 mo after treatment. Four patients of topiramate group appeared temporary adverse reactions of central nervous system, such as tiredness, sleepiness and distraction, but one patient of sodium valproate group had severer decreased function of bone marrow. CONCLUSION: Topiramate is one of effective antiepileptic drugs and superior to slow-release sodium valproate. There are the apparent absence of any effects of topiramate on the bone marrow and on indexes of liver and kidney.
